6,7-dimethoxy-4-(2-methyl-4-nitrophenoxy)quinoline | 347161-73-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6,7-dimethoxy-4-(2-methyl-4-nitrophenoxy)quinoline
• 英文别名: 4-(2-Methyl-4-nitrophenoxy)-6,7-dimethoxyquinoline
• CAS: 347161-73-3
• 化学式: C₁₈H₁₆N₂O₅
• 分子量: 340.335
• InChiKey: VBEIMFZUDCIBQS-UHFFFAOYSA-N

物化性质

• 熔点：
  156-157 °C
• 沸点：
  489.3±40.0 °C(Predicted)
• 密度：
  1.291±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  86.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  6,7-dimethoxy-4-(2-methyl-4-nitrophenoxy)quinoline 生成 4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-methylaniline
  参考文献：
  名称：

  Orally active anti-proliferation agents: novel diphenylamine derivatives as FGF-R2 autophosphorylation inhibitors

  摘要：

  (6,7-二取代喹啉-4-基氧苯基)(4-取代苯基)胺衍生物通过在人瘢痕胃癌细胞系OCUM-2MD3中进行成纤维细胞生长因子受体2（FGF-R2）的细胞自体磷酸化试验而被合成和评估。我们还进行了代谢稳定性研究，结果显示喹啉环7位的取代基会影响其生物稳定性。在本研究中，我们显著改善了双苯胺衍生物的溶解性和代谢稳定性。最具潜力的化合物15e在口服给药时表现出肿瘤体积的显著减少。 ©2003 Elsevier Ltd. 保留所有权利。

  DOI：

  10.1016/j.bmcl.2003.12.019
• 作为产物：
  描述：

  2-甲基-4-硝基苯酚 、 4-氯 -6,7-二甲氧基喹啉 以 氯苯 为溶剂， 生成 6,7-dimethoxy-4-(2-methyl-4-nitrophenoxy)quinoline
  参考文献：
  名称：

  Orally active anti-proliferation agents: novel diphenylamine derivatives as FGF-R2 autophosphorylation inhibitors

  摘要：

  (6,7-二取代喹啉-4-基氧苯基)(4-取代苯基)胺衍生物通过在人瘢痕胃癌细胞系OCUM-2MD3中进行成纤维细胞生长因子受体2（FGF-R2）的细胞自体磷酸化试验而被合成和评估。我们还进行了代谢稳定性研究，结果显示喹啉环7位的取代基会影响其生物稳定性。在本研究中，我们显著改善了双苯胺衍生物的溶解性和代谢稳定性。最具潜力的化合物15e在口服给药时表现出肿瘤体积的显著减少。 ©2003 Elsevier Ltd. 保留所有权利。

  DOI：

  10.1016/j.bmcl.2003.12.019

文献信息

• Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors
  作者：Yun Wu、Beilei Wang、Junjie Wang、Shuang Qi、Fengming Zou、Ziping Qi、Feiyang Liu、Qingwang Liu、Cheng Chen、Chen Hu、Zhenquan Hu、Aoli Wang、Li Wang、Wenchao Wang、Tao Ren、Yujiao Cai、Mingfeng Bai、Qingsong Liu、Jing Liu

  DOI：10.1021/acs.jmedchem.9b00280

  日期：2019.7.11

  Starting from our previously developed c-KIT kinase inhibitor CHMFL-KIT-8140, through a type II kinase inhibitor binding element hybrid design approach, we discovered a novel c-KIT kinase inhibitor compound 18 (CHMFL-KIT-64), which is potent against c-KIT wt and a broad spectrum of drug-resistant mutants with improved bioavailability. 18 exhibits single-digit nM potency against c-KIT kinase and c-KIT

  从我们先前开发的c-KIT激酶抑制剂CHMFL-KIT-8140开始，通过II型激酶抑制剂结合元件杂交设计方法，我们发现了一种新型的c-KIT激酶抑制剂化合物18（CHMFL-KIT-64），对抗c-KIT wt和具有改善的生物利用度的广谱耐药突变体。18在生化分析中显示出对c-KIT激酶和c-KIT T670I突变体的个位数nM效价，并且对近膜域中大多数功能获得性突变，ATP结合口袋中的耐药性突变均显示出极大的效价（V654A除外）和激活循环（D816V除外）。此外，18在不同物种（包括小鼠，大鼠和狗）中表现出良好的体内药代动力学（PK）特性。它还在c-KIT T670I，D820G，和Y823D突变体介导的小鼠模型以及在已知对伊马替尼具有抗性的c-KIT wt患者原代细胞中。结合广泛的临床重要c-KIT突变体的强大活性（具有良好的体内PK /药效学特性18）表明，它可能是胃肠道间质瘤的新潜在治疗候选物。
• [EN] QUINOLINE DERIVATIVES AS INHIBITORS OF AXL/MER RTK AND CSF1R<br/>[FR] DÉRIVÉS DE QUINOLÉINE UTILISÉS EN TANT QU'INHIBITEURS D'AXL/MER RTK ET CSF1R
  申请人：QURIENT CO LTD

  公开号：WO2019229251A1

  公开（公告）日：2019-12-05

  The present invention relates to quinoline derivatives which are inhibitors for Axl/Mer RTK (receptor tyrosine kinase) and CSF1R (colony stimulating factor 1 receptor). These compounds are suitable for the treatment of disorders associated with, accompanied by, caused by or induced by Axl/Mer RTK and CSF1R, in particular a hyperfunction thereof. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly immune-suppressive cancer (such as those cancers with an immunosuppression of innate immunity in a tumor microenvironment (TME), refractory cancer and cancer metastases. They are also useful in the treatment of inflammatory diseases and/or neurodegenerative diseases.

  本发明涉及喹啉衍生物，其为Axl/Mer RTK（受体酪氨酸激酶）和CSF1R（集落刺激因子1受体）的抑制剂。这些化合物适用于治疗与Axl/Mer RTK和CSF1R相关、伴随、由其引起或诱导的疾病，特别是其中的过度功能。这些化合物适用于治疗过度增殖性疾病，如癌症，特别是免疫抑制性癌症（例如在肿瘤微环境中具有天然免疫抑制的癌症、难治性癌症和癌症转移）。它们还可用于治疗炎症性疾病和/或神经退行性疾病。
• Quinoline and quinazoline derivatives and drugs containing the same
  申请人：——

  公开号：US20040132727A1

  公开（公告）日：2004-07-08

  There are provided compounds which can be used in the treatment of diseases mediated by the autophosphorylation of a PDGF receptor, specifically, compounds which can inhibit neointima formation hypertrophy. The compounds are those represented by formula (I) or pharmacologically acceptable salts or solvates thereof: 1 wherein R 1 and R 2 represent hydrogen, alkyl or the like; R 3 , R 4 , R 5 and R 6 represent hydrogen, halogen, alkyl, alkoxy or the like; R 11 and R 12 represent hydrogen, alkyl, alkylcarbonyl or the like; and A represents any one of formulae (i) to (x), provided that compounds wherein R 3 , R 4 , R 5 and R 6 represent hydrogen and A represents group (v) wherein u is 0 (zero) and R 19 represents phenyl optionally substituted by halogen, alkyl, or alkoxy are excluded.

  提供了一些化合物，可用于治疗由PDGF受体自磷酸化介导的疾病，特别是可抑制新内膜形成肥大的化合物。这些化合物由式（I）或其药理学上可接受的盐或溶剂表示：1其中R1和R2表示氢，烷基或类似物；R3、R4、R5和R6表示氢，卤素，烷基，烷氧基或类似物；R11和R12表示氢，烷基，烷基羰基或类似物；而A表示公式（i）到（x）中的任意一个，但其中R3、R4、R5和R6表示氢，A表示组（v）其中u为0（零）且R19表示苯基，可选地被卤素，烷基或烷氧基取代的化合物被排除。
• QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：EP1243582A1

  公开（公告）日：2002-09-25

  There are provided compounds which can be used in the treatment of diseases mediated by the autophosphorylation of a PDGF receptor, specifically, compounds which can inhibit neointima formation hypertrophy. The compounds are those represented by formula (I) or pharmacologically acceptable salts or solvates thereof: wherein R1 and R2 represent hydrogen, alkyl or the like; R3, R4, R5, and R6 represent hydrogen, halogen, alkyl, alkoxy or the like; R11 and R12 represent hydrogen, alkyl, alkylcarbonyl or the like; and A represents any one of formulae (i) to (x), provided that compounds wherein R3, R4, R5 and R6 represent hydrogen and A represents group (v) wherein u is 0 (zero) and R19 represents phenyl optionally substituted by halogen, alkyl, or alkoxy are excluded.

  提供了可用于治疗由 PDGF 受体自身磷酸化介导的疾病的化合物，特别是可抑制新内膜形成肥厚的化合物。这些化合物是式 (I) 所代表的化合物或其药理学上可接受的盐或溶液： 其中 R1 和 R2 代表氢、烷基或类似物；R3、R4、R5 和 R6 代表氢、卤素、烷基、烷氧基或类似物；R11 和 R12 代表氢、烷基、烷基羰基或类似物；A 代表式(i)至(x)中的任意一种，但不包括 R3、R4、R5 和 R6 代表氢且 A 代表基团(v)（其中 u 为 0（零）且 R19 代表任选被卤素、烷基或烷氧基取代的苯基）的化合物。
• Discovery of <i>N</i>-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors
  作者：István Szabadkai、Robert Torka、Rita Garamvölgyi、Ferenc Baska、Pál Gyulavári、Sándor Boros、Eszter Illyés、Axel Choidas、Axel Ullrich、László Őrfi

  DOI：10.1021/acs.jmedchem.8b00672

  日期：2018.7.26

  The overexpression of AXL kinase has been described in many types of cancer. Due to its role in proliferation, survival, migration, and resistance, AXL represents a promising target in the treatment of the disease. In this study we present a novel compound family that successfully targets the AXL kinase. Through optimization and detailed SAR studies we developed low nanomolar inhibitors, and after further biological characterization we identified a potent AXL kinase inhibitor with favorable pharmacokinetic profile. The antitumor activity was determined in xenograft models, and the lead compounds reduced the tumor size by 40% with no observed toxicity as well as lung metastasis formation by 66% when compared to vehicle control.